low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. Patient enrollment in IBD trials continues regardless of economic conditions as these are serious chronic diseases. However, severe recessions can impact: (1) ability to raise capital at attractive valuations, (2) pharmaceutical company M&A appetite for partnerships, and (3) healthcare system capacity to conduct trials during crises.

Rising interest rates negatively impact pre-revenue biotechnology valuations through two mechanisms: (1) Higher discount rates applied to distant future cash flows (potential product revenues 4-7+ years out) compress present values significantly, and (2) Risk-free rate competition makes speculative biotech less attractive versus bonds. Additionally, higher rates increase opportunity cost of cash holdings (~$115M cash earning higher yields is modest offset). Rate cuts typically benefit high-growth, long-duration biotech assets.

growth - High-risk, high-reward clinical-stage biotech attracts speculative growth investors and specialized healthcare funds willing to accept binary outcomes. Investors are betting on clinical trial success creating 3-10x returns through regulatory approval, partnership deals, or acquisition. No dividends, negative earnings, and high volatility make this unsuitable for value or income investors. Momentum traders enter around clinical catalysts (data readouts, FDA decisions). Typical holders include biotech-focused hedge funds, venture capital, and retail investors with high risk tolerance.